Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Investors Are Too Spooked by Washington's PBM Crackdown
Efforts to take on Cigna’s and CVS’s pharmacy benefit managers won’t hurt as much as Wall Street expects. Source link
FTC Rejects Illumina's $7 Billion Deal for Cancer-Test Developer Grail
The agency said the combination would hurt competition for cancer-detection tests while raising prices. Source link
The 'King Kong' of Weight-Loss Drugs Is Coming
Eli Lilly’s Mounjaro could outpace Ozempic as the most powerful treatment on the market. To develop it, the drug company needed to overhaul long-held but
Telemedicine Startups Wary of Regulatory Shift in War on Opioid Addiction
Telemedicine companies are facing a regulatory shift that many entrepreneurs say would undercut their ability to quickly prescribe medication that helps prevent opioid overdoses. During
Dreaded Medical Paperwork Required by Health Insurers to Be Trimmed
WSJ News Exclusive Health UnitedHealthcare, Cigna and Aetna move to revamp prior-authorization programs Source link
Carl Icahn Wants to Bring Illumina’s Old CEO Back, Disney-Style
WSJ News Exclusive Heard on the Street Billionaire activist signals he wants company’s retired CEO Jay Flatley to come back and Grail divested Source link
Americans to Be Barred From Buying Ozempic in British Columbia
Provincial health officials urged doctors and pharmacists to make sure people are taking the drug to treat diabetes, not lose weight. Source link
Former Aetna CEO to Take Helm of Health Insurer Oscar
WSJ News Exclusive Health Mark Bertolini was most recently the co-chief executive of hedge fund Bridgewater Associates Source link
Ex-FDA Official Says Baby-Formula Industry Remains Vulnerable to Problems
Politics Health Policy Poor internal communication hindered FDA’s response to crisis, former deputy commissioner says in congressional testimony Source link
Drug Middlemen Accused of Price Fixing by Ohio Attorney General
The state’s lawsuit alleged certain pharmacy-benefit managers shared drug pricing and other information to gain leverage during rebate negotiations with pharmaceutical companies. Source link
